Opyl Ltd's (ASX:OPL) Michelle Gallaher updates Proactive's Andrew Scott on developments with their clinical predictor and clinical trials recruitment platforms. The company's developed software that uses artificial intelligence (AI) to make a probability of success prediction on the likelihood of a vaccine, drug, diagnostic or medical device succeeding in clinical trials.
Opyl Ltd CEO says successful COVID-19 data trial is validation of its platform
Quick facts: Opyl Ltd
Price: 0.175 AUD
Market Cap: $9.52 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...FOR OUR FULL DISCLAIMER CLICK HERE